Form 4: Kestra Medical CEO Sells 15,000 Shares Under 10b5-1 Plan

Kestra Medical Technologies' President and CEO, Brian Daniel Webster, sold 15,000 common shares for approximately $20.27 per share as part of a pre-arranged trading plan.

Summary

• Brian Daniel Webster, President and CEO of Kestra Medical Technologies, Ltd. (KMTS), disposed of 15,000 common shares.
• The transaction occurred on March 17, 2026, at a weighted average price of $20.2749 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
• Following this transaction, Mr. Webster directly beneficially owns 364,786 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale reduces direct ownership, its execution under a pre-planned 10b5-1 arrangement mitigates concerns about opportunistic trading.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate material non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct equity stake in the company.

Management Comments

• The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
• The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.0000 to $20.7709.

Industry Context

StockSavvy.ai notes that insider sales, particularly by a CEO, are often scrutinized by investors for potential signals about future company performance. However, sales executed under a pre-arranged 10b5-1 plan are generally viewed as less indicative of management's immediate sentiment, as these plans are set up in advance to allow insiders to diversify holdings without being accused of trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the sale as a slight negative signal, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

The insider sale by the CEO, while reducing his direct stake, was conducted under a pre-arranged 10b5-1 plan. This suggests a planned diversification rather than a reaction to new negative information. Without additional context on the company's performance or other market factors, this single transaction does not warrant a change from a 'hold' position.

Keywords

Kestra Medical Technologies, KMTS, Insider Sale, Form 4, Brian Daniel Webster, 10b5-1 Plan, Equity Transaction, CEO Stock Sale